quinolinic acid has been researched along with Multiple Sclerosis in 7 studies
Quinolinic Acid: A metabolite of tryptophan with a possible role in neurodegenerative disorders. Elevated CSF levels of quinolinic acid are correlated with the severity of neuropsychological deficits in patients who have AIDS.
pyridinedicarboxylic acid : Any member of the class of pyridines carrying two carboxy groups.
quinolinic acid : A pyridinedicarboxylic acid that is pyridine substituted by carboxy groups at positions 2 and 3. It is a metabolite of tryptophan.
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The excitotoxin quinolinic acid, a by-product of the kynurenine pathway, is known to be involved in several neurological diseases including multiple sclerosis (MS)." | 7.80 | Quinolinic acid toxicity on oligodendroglial cells: relevance for multiple sclerosis and therapeutic strategies. ( Adams, S; Brew, BJ; Guillemin, GJ; Jones, SP; Lim, CK; Sundaram, G, 2014) |
| "Researches have been shown that glutamic acid (GA) or quinolinic acid (QA) can play role in neuroinflammatory and demyelinating diseases including multiple sclerosis (MS), mainly via oligodendrocytes activation and extreme free radicals generation." | 3.91 | Safranal Attenuates Excitotoxin-Induced Oxidative OLN-93 Cells Injury. ( Alavi, MS; Barzegar, H; Fanoudi, S; Fard, AV; Hosseini, M; Sadeghnia, HR; Soukhtanloo, M, 2019) |
| "The excitotoxin quinolinic acid, a by-product of the kynurenine pathway, is known to be involved in several neurological diseases including multiple sclerosis (MS)." | 3.80 | Quinolinic acid toxicity on oligodendroglial cells: relevance for multiple sclerosis and therapeutic strategies. ( Adams, S; Brew, BJ; Guillemin, GJ; Jones, SP; Lim, CK; Sundaram, G, 2014) |
| "In patients with encephalopathy, serum QUIN was elevated with corresponding increments in CSF QUIN." | 1.28 | Neuroactive kynurenines in Lyme borreliosis. ( Halperin, JJ; Heyes, MP, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Fathi, M | 3 |
| Vakili, K | 3 |
| Yaghoobpoor, S | 3 |
| Tavasol, A | 3 |
| Jazi, K | 3 |
| Mohamadkhani, A | 3 |
| Klegeris, A | 3 |
| McElhinney, A | 3 |
| Mafi, Z | 3 |
| Hajiesmaeili, M | 3 |
| Sayehmiri, F | 3 |
| Isık, SMT | 1 |
| Onmaz, DE | 1 |
| Ekmekci, AH | 1 |
| Ozturk, S | 1 |
| Unlu, A | 1 |
| Abusoglu, S | 1 |
| Alavi, MS | 1 |
| Fanoudi, S | 1 |
| Fard, AV | 1 |
| Soukhtanloo, M | 1 |
| Hosseini, M | 1 |
| Barzegar, H | 1 |
| Sadeghnia, HR | 1 |
| Sundaram, G | 1 |
| Brew, BJ | 2 |
| Jones, SP | 1 |
| Adams, S | 1 |
| Lim, CK | 1 |
| Guillemin, GJ | 2 |
| Anderson, G | 1 |
| Rodriguez, M | 1 |
| Kerr, SJ | 1 |
| Pemberton, LA | 1 |
| Smith, DG | 1 |
| Smythe, GA | 1 |
| Armati, PJ | 1 |
| Halperin, JJ | 1 |
| Heyes, MP | 1 |
2 reviews available for quinolinic acid and Multiple Sclerosis
| Article | Year |
|---|---|
Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.
Topics: Humans; Kynurenic Acid; Kynurenine; Leukocytes, Mononuclear; Multiple Sclerosis; Quinolinic Acid; Tr | 2022 |
Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.
Topics: Humans; Kynurenic Acid; Kynurenine; Leukocytes, Mononuclear; Multiple Sclerosis; Quinolinic Acid; Tr | 2022 |
Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.
Topics: Humans; Kynurenic Acid; Kynurenine; Leukocytes, Mononuclear; Multiple Sclerosis; Quinolinic Acid; Tr | 2022 |
Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.
Topics: Humans; Kynurenic Acid; Kynurenine; Leukocytes, Mononuclear; Multiple Sclerosis; Quinolinic Acid; Tr | 2022 |
Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.
Topics: Humans; Kynurenic Acid; Kynurenine; Leukocytes, Mononuclear; Multiple Sclerosis; Quinolinic Acid; Tr | 2022 |
Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.
Topics: Humans; Kynurenic Acid; Kynurenine; Leukocytes, Mononuclear; Multiple Sclerosis; Quinolinic Acid; Tr | 2022 |
Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.
Topics: Humans; Kynurenic Acid; Kynurenine; Leukocytes, Mononuclear; Multiple Sclerosis; Quinolinic Acid; Tr | 2022 |
Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.
Topics: Humans; Kynurenic Acid; Kynurenine; Leukocytes, Mononuclear; Multiple Sclerosis; Quinolinic Acid; Tr | 2022 |
Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.
Topics: Humans; Kynurenic Acid; Kynurenine; Leukocytes, Mononuclear; Multiple Sclerosis; Quinolinic Acid; Tr | 2022 |
Multiple sclerosis, seizures, and antiepileptics: role of IL-18, IDO, and melatonin.
Topics: Anticonvulsants; Comorbidity; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Interferon-gamma; Interl | 2011 |
5 other studies available for quinolinic acid and Multiple Sclerosis
| Article | Year |
|---|---|
Relationship of tryptophan metabolites with the type and severity of multiple sclerosis.
Topics: Animals; Humans; Kynurenic Acid; Kynurenine; Mammals; Multiple Sclerosis; Quinolinic Acid; Tryptopha | 2023 |
Safranal Attenuates Excitotoxin-Induced Oxidative OLN-93 Cells Injury.
Topics: Animals; Antioxidants; Cell Survival; Cyclohexenes; Glutamic Acid; Multiple Sclerosis; Neurotoxins; | 2019 |
Quinolinic acid toxicity on oligodendroglial cells: relevance for multiple sclerosis and therapeutic strategies.
Topics: Animals; Antibodies, Monoclonal; Cell Line; Cell Line, Transformed; Encephalomyelitis, Autoimmune, E | 2014 |
IFN-beta1b induces kynurenine pathway metabolism in human macrophages: potential implications for multiple sclerosis treatment.
Topics: Cells, Cultured; Dose-Response Relationship, Drug; Humans; Interferon beta-1a; Interferon beta-1b; I | 2001 |
Neuroactive kynurenines in Lyme borreliosis.
Topics: Brain Diseases; Humans; Kynurenine; Lyme Disease; Lymphokines; Multiple Sclerosis; Nervous System Di | 1992 |